At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AMGN Amgen
Post-Mkt 08-05 16:20:28 EDT
407.83
+17.81
+4.57%
盘后408.80
+0.97+0.24%
16:18 EDT
High416.24Low391.00Vol5.56M
Open393.36D1 Closing390.02Amplitude6.47%
Mkt Cap219.61BTradable Cap219.00BTotal Shares538.48M
T/O2.26BT/O Rate1.03%Tradable Shares536.99M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence
Reuters  ·  08-05 22:45
Wall Street Warms to Healthcare Stocks as Tech Trade Faces Turbulence
Amgen is Maintained at Equal-Weight by Wells Fargo
Dow Jones  ·  08-05 23:03
Amgen is Maintained at Equal-Weight by Wells Fargo
NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-08-05
Reuters  ·  08-05 23:01
NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-08-05
Amgen Jolts to Record-High After Hiking FY Forecasts, Q2 Results Beat
Reuters  ·  08-05 22:40
Amgen Jolts to Record-High After Hiking FY Forecasts, Q2 Results Beat
Amgen Shares Hit Record High; Last up 6.3% at $414.61
THOMSON REUTERS  ·  08-05 22:09
Amgen Shares Hit Record High; Last up 6.3% at $414.61
Amgen price target raised to $440 from $420 at UBS
TIPRANKS  ·  08-05 22:01
Amgen price target raised to $440 from $420 at UBS
Amgen Shares up 5% After Q2 Results Beat Estimates; FY Profit Forecast Raise
THOMSON REUTERS  ·  08-05 21:55
Amgen Shares up 5% After Q2 Results Beat Estimates; FY Profit Forecast Raise
Dow's 500-Point Rally Led by Gains in Amgen, Nvidia Corp. Shares
Dow Jones  ·  08-05 21:45
Dow's 500-Point Rally Led by Gains in Amgen, Nvidia Corp. Shares
Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance
Market Focus  ·  08-05 21:43
Movement Alert｜Amgen Rises 4.2% in Regular Trading, Q2 Earnings Significantly Beat Expectations with Raised Full-Year Guidance
Amgen Inc : Canaccord Genuity Raises Target Price to $384 from $366
THOMSON REUTERS  ·  08-05 21:14
Amgen Inc : Canaccord Genuity Raises Target Price to $384 from $366
Immuneering Expects Cash Runway to Fund Operations into 2029
Reuters  ·  08-05 19:40
Immuneering Expects Cash Runway to Fund Operations into 2029
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)
TIPRANKS  ·  08-05 19:40
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)
Morgan Stanley Adjusts Price Target on Amgen to $351 From $333, Maintains Equalweight Rating
MT Newswires Live  ·  08-05 17:44
Morgan Stanley Adjusts Price Target on Amgen to $351 From $333, Maintains Equalweight Rating
Amgen Inc : Scotiabank Raises Target Price to $450 from $385
THOMSON REUTERS  ·  08-05 17:20
Amgen Inc : Scotiabank Raises Target Price to $450 from $385
Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong
Dow Jones  ·  08-05 16:32
Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong
Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting
Reuters  ·  08-05 16:24
Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting
U.S. Research Roundup-Ametek, Ball Corp, McDonald's
Reuters  ·  08-05 15:55
U.S. Research Roundup-Ametek, Ball Corp, McDonald's
Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333
THOMSON REUTERS  ·  08-05 14:30
Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333
Amgen Inc : Oppenheimer Raises Target Price to $450 from $400
THOMSON REUTERS  ·  08-05 11:10
Amgen Inc : Oppenheimer Raises Target Price to $450 from $400
TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)
TIPRANKS  ·  08-05 10:57
TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)

Introduction

Company Name.
Amgen
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Issue price:
--